Clinical and Experimental Medicine

, Volume 12, Issue 3, pp 165–171

High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk non-Hodgkin lymphoma

  • Franca Falzetti
  • Mauro Di Ianni
  • Stelvio Ballanti
  • Giuseppe Iodice
  • Antonia Reale
  • Olivia Minelli
  • Gabriella Serio
  • Massimo F. Martelli
  • Franco Dammacco
  • Angelo Vacca
  • Roberto Ria
Original Article

DOI: 10.1007/s10238-011-0157-2

Cite this article as:
Falzetti, F., Ianni, M.D., Ballanti, S. et al. Clin Exp Med (2012) 12: 165. doi:10.1007/s10238-011-0157-2

Abstract

High-dose chemotherapy conditioning regimens followed by autologous stem cell transplantation generally provide good results in non-Hodgkin lymphoma. We have evaluated the effects of a high-dose regimen comprising thiotepa, etoposide and carboplatin. After debulking and mobilization with high-dose cyclophosphamide or other schedules, forty-five patients at various disease stages were conditioned with thiotepa, etoposide and carboplatin prior to autologous stem cell transplantation. The overall response rate was 77.8% (30 CR, 66.7%; 5 PR, 11.1%). Ten patients (22.2%) did not respond. Two patients (4.4%) died from transplant-related complications. The mean 5-year overall survival was 71.1%: 12 patients relapsed within the first 5 years of follow-up. The overall response rate and 5-year overall survival were better for patients with an International Prognostic Index (IPI) 1 at diagnosis than for those with IPI 2 and IPI 3 (P < 0.005 for all). The thiotepa, etoposide and carboplatin conditioning regimen for autologous stem cell transplantation in non-Hodgkin lymphoma has a good anti-lymphoma effect and provides encouraging results in terms of response to treatment and 5-year overall survival. Its good tolerance and acceptable toxicity suggest that it may a very useful in the management of non-Hodgkin lymphoma.

Keywords

Autologous stem cell transplantationConditioning regimenHigh-dose chemotherapyNon-Hodgkin lymphomaSurvival

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Franca Falzetti
    • 1
  • Mauro Di Ianni
    • 1
  • Stelvio Ballanti
    • 1
  • Giuseppe Iodice
    • 2
  • Antonia Reale
    • 2
  • Olivia Minelli
    • 3
  • Gabriella Serio
    • 4
  • Massimo F. Martelli
    • 1
  • Franco Dammacco
    • 2
  • Angelo Vacca
    • 2
  • Roberto Ria
    • 2
  1. 1.Department of Clinical and Experimental MedicineSection of Hematology and Clinical Immunology, University of Perugia Medical SchoolPerugiaItaly
  2. 2.Department of Biomedical Sciences and Human OncologySection of Internal Medicine and Clinical Oncology, University of BariBariItaly
  3. 3.Immunohematology and Blood Transfusion Service, Perugia General HospitalPerugiaItaly
  4. 4.Section of Medical StatisticsUniversity of Bari Medical SchoolBariItaly